Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Cell Exosome Solution in ALS and Motor Disorders
NCT07105371Phase 1Completed
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial in amyotrophic lateral sclerosis (ALS) and Motor disorder, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 6 months. Started Jul 2024; status: completed.
02
Conditions
amyotrophic lateral sclerosis (ALS)Motor disorder
Beyond the preview
Go deeper on NCT07105371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105371.